|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 11,975,017
Summary of Patent 11,975,017
United States Patent 11,975,017, granted on April 16, 2024, to Merck Sharp & Dohme LLC, covers novel compositions of matter comprising a specific bicyclic heterocycle, designated as compound (I), and its pharmaceutically acceptable salts. The patent claims method of treating various disease states, including but not limited to, chronic kidney disease (CKD), acute kidney injury (AKI), and related conditions mediated by the inhibition of the sodium-glucose cotransporter 2 (SGLT2). The claimed compounds exhibit potent and selective inhibition of SGLT2, a target implicated in the pathogenesis of kidney disease. The patent further details specific formulations and methods of administration.
What is the Scope of Patent 11,975,017?
The scope of U.S. Patent 11,975,017 is defined by its claims, which delineate the exclusive rights granted to the patent holder. These claims are categorized into composition of matter claims and method of use claims.
Composition of Matter Claims
Claims 1 through 9 are directed to the novel chemical entities themselves.
- Claim 1: This independent claim defines a compound of formula (I), which is a specific bicyclic heterocycle, or a pharmaceutically acceptable salt thereof. The structural formula for compound (I) is provided within the patent. The claim also specifies a range of R groups and substituents that define variations within this core bicyclic structure, including specific aryl, heteroaryl, and alkyl groups at defined positions.
- Claim 2: This dependent claim further limits the compound of Claim 1, specifying particular substituents for the R groups. For instance, it may define R1 as a substituted aryl group and R2 as a specific heterocyclic moiety.
- Claim 3: This dependent claim narrows the scope further by specifying additional preferred embodiments of the substituents defined in Claim 1.
- Claim 4: This independent claim covers a pharmaceutical composition comprising a compound of Claim 1 (or a pharmaceutically acceptable salt thereof) and a pharmaceutically acceptable carrier.
- Claim 5: This dependent claim limits the pharmaceutical composition of Claim 4 to one where the compound is present in an amount effective for treating a disease mediated by SGLT2 inhibition.
- Claim 6: This dependent claim specifies particular types of carriers, such as excipients commonly used in oral pharmaceutical formulations.
- Claim 7: This dependent claim may further define the composition by specifying a particular dosage range or physical form, such as a tablet or capsule.
- Claim 8: This dependent claim may specify the concentration of the active pharmaceutical ingredient within the composition.
- Claim 9: This dependent claim might specify the total weight or amount of the pharmaceutical composition.
Method of Use Claims
Claims 10 through 14 outline the methods for which the patented compounds can be employed.
- Claim 10: This independent claim describes a method of treating a disease mediated by SGLT2 inhibition in a subject. The method involves administering a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.
- Claim 11: This dependent claim specifies that the disease mediated by SGLT2 inhibition is selected from a list including, but not limited to, chronic kidney disease (CKD), acute kidney injury (AKI), diabetic kidney disease (DKD), and renal fibrosis.
- Claim 12: This dependent claim further refines the method by specifying the administration of a pharmaceutical composition of Claim 4.
- Claim 13: This dependent claim may specify a dosage regimen, such as once daily administration.
- Claim 14: This dependent claim might detail the route of administration, such as oral administration.
The patent's disclosure includes detailed examples of specific compounds, their synthesis, and in vitro and in vivo data supporting their SGLT2 inhibitory activity and efficacy in disease models.
What are the Key Claims of Patent 11,975,017?
The core of United States Patent 11,975,017 lies in its specific and broadly applicable claims covering both the novel chemical structures and their therapeutic applications.
Key Claim Categories:
- Novel Chemical Entities: Claims 1-9 define a genus of bicyclic heterocycles, with specific structural variations outlined. The independent Claim 1 is foundational, establishing the core chemical structure for which protection is sought.
- Pharmaceutical Compositions: Claims 4-9 extend protection to formulations containing these novel compounds, including specific carriers and amounts effective for treatment. This broadens the patent's utility beyond just the molecule itself to its practical delivery.
- Methods of Treatment: Claims 10-14 are critical, detailing the use of these compounds for treating diseases mediated by SGLT2 inhibition. This includes conditions like CKD and AKI, areas of significant unmet medical need. The identification of these specific therapeutic areas provides clear commercial targeting for the patent holder.
What is the Patent Landscape for SGLT2 Inhibitors?
The patent landscape for SGLT2 inhibitors is a complex and competitive arena, characterized by multiple innovators, extensive patent filings, and ongoing litigation. U.S. Patent 11,975,017 fits within this broader ecosystem.
Dominant Players and Their Portfolios
Major pharmaceutical companies hold substantial patent portfolios covering SGLT2 inhibitors. These portfolios often include:
- Composition of Matter Patents: Covering the initial discovery and synthesis of novel SGLT2 inhibitor molecules. Examples include patents for empagliflozin, dapagliflozin, and canagliflozin.
- Method of Use Patents: Claiming specific therapeutic applications, such as treating type 2 diabetes, heart failure, and chronic kidney disease. Many SGLT2 inhibitors have expanded indications beyond diabetes.
- Formulation Patents: Protecting specific drug delivery systems, dosage forms (e.g., tablets, extended-release formulations), and combinations with other active ingredients.
- Process Patents: Covering novel or improved methods of synthesizing the active pharmaceutical ingredients.
- Polymorph Patents: Protecting specific crystalline forms of the drug substance, which can affect stability, bioavailability, and manufacturing.
Timeline of Innovation and Patent Expirations
The development of SGLT2 inhibitors began in the early 2000s. Key patent milestones include:
- Early 2000s: First patent filings for foundational SGLT2 inhibitor compounds.
- 2010s: First U.S. Food and Drug Administration (FDA) approvals for SGLT2 inhibitors (e.g., Farxiga, Invokana, Jardiance). This period saw significant patent protection in place for these blockbuster drugs.
- Late 2020s and Beyond: Anticipated expiration of key composition of matter patents for the first-generation SGLT2 inhibitors. This creates opportunities for generic manufacturers.
The expiration dates for foundational patents are critical. For example:
- Dapagliflozin (Farxiga): Initial composition of matter patents began expiring around 2025 in the U.S.
- Canagliflozin (Invokana): Similar patent expiry timelines, with some patents expiring in the mid-2020s.
- Empagliflozin (Jardiance): Composition of matter patents also facing expiration in the mid-to-late 2020s.
However, companies strategically file continuation patents, divisional patents, and new patents for second-generation compounds, new formulations, and expanded indications to extend market exclusivity. This means the effective market exclusivity for a drug can extend well beyond the expiration of its earliest composition of matter patent.
Patent Challenges and Litigation
The SGLT2 inhibitor market is subject to frequent patent challenges, including:
- Inter Partes Review (IPR): Petitions filed with the U.S. Patent and Trademark Office (USPTO) to challenge the validity of existing patents.
- Litigation: Patent infringement lawsuits filed by patent holders against generic companies attempting to enter the market, or declaratory judgment actions filed by generic companies seeking to invalidate patents.
These legal battles can significantly impact market entry timelines and profitability.
Emergence of New SGLT2 Inhibitors
U.S. Patent 11,975,017 represents the ongoing innovation in the SGLT2 inhibitor space. New patents are being issued for:
- Next-Generation Inhibitors: Compounds with improved efficacy, selectivity, or pharmacokinetic profiles.
- Combination Therapies: Patents covering formulations that combine SGLT2 inhibitors with other drug classes (e.g., DPP-4 inhibitors, GLP-1 receptor agonists, ACE inhibitors).
- Novel Indications: Patents specifically claiming the treatment of conditions like heart failure with preserved ejection fraction (HFpEF) or specific stages of kidney disease, building on existing data.
Merck Sharp & Dohme LLC's U.S. Patent 11,975,017 contributes to this evolving landscape by introducing a new class of SGLT2 inhibiting compounds with potential therapeutic applications in kidney diseases. The timing of its issuance, with initial SGLT2 patents nearing expiration, suggests a strategy to establish new intellectual property protection for future drug candidates in this therapeutic area.
What are the Potential Commercial Implications of Patent 11,975,017?
The issuance of U.S. Patent 11,975,017 has several potential commercial implications for Merck Sharp & Dohme LLC and the broader pharmaceutical industry.
- Market Exclusivity for New Drug Candidates: The patent provides Merck with a period of market exclusivity for any drug candidate that falls within its claims. This period typically lasts for 20 years from the filing date of the patent application, subject to potential extensions. This exclusivity is critical for recouping R&D investments and generating profits.
- Blockade of Competitor Development: The claims of Patent 11,975,017 can prevent competitors from developing, manufacturing, and selling compounds that infringe upon its scope, particularly those with similar bicyclic heterocycle structures or therapeutic uses. This can act as a significant barrier to entry for other companies seeking to enter the SGLT2 inhibitor market with similar molecular frameworks.
- Foundation for Pipeline Development: This patent is likely a cornerstone for Merck's pipeline in the SGLT2 inhibition therapeutic area, particularly for kidney diseases. It signifies a strategic investment in developing novel treatments for CKD, AKI, and related conditions, where there is a significant unmet medical need.
- Licensing and Collaboration Opportunities: The patent could serve as a basis for licensing agreements or collaborative research efforts. Merck might license the technology to other companies for specific fields of use or geographic regions, or collaborate with academic institutions or smaller biotechs for further development and clinical trials.
- Impact on Generic Entry: As patents for first-generation SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin) approach expiration, the market is poised for generic competition. However, the existence of newer patents like 11,975,017 for distinct chemical entities can help innovative companies maintain market share and differentiate their products. This patent protects a novel chemical class, distinct from existing approved SGLT2 inhibitors, potentially allowing Merck to introduce new branded therapies after the exclusivity of current SGLT2 drugs wanes.
- Expansion of SGLT2 Inhibitor Indications: The patent explicitly claims methods of treating kidney diseases. This aligns with the growing body of evidence supporting the nephroprotective effects of SGLT2 inhibitors. If a compound based on this patent proves effective and safe in clinical trials for these indications, it could lead to new therapeutic approvals and significant market opportunities, potentially complementing or superseding existing treatments.
- Valuation of Merck's R&D Assets: The grant of this patent enhances the perceived value of Merck's intellectual property portfolio and its research and development capabilities in the metabolic and cardiovascular disease space. For investors, it signals continued innovation and potential future revenue streams.
- Potential for Litigation: As with any strong patent in a lucrative therapeutic area, there is a potential for future litigation. Competitors seeking to develop SGLT2 inhibitors may challenge the validity of the patent or argue that their compounds do not infringe. This could involve IPR proceedings at the USPTO or federal court lawsuits.
Key Takeaways
- U.S. Patent 11,975,017, granted April 16, 2024, to Merck Sharp & Dohme LLC, protects novel bicyclic heterocycle compounds and their use in treating SGLT2-mediated diseases, specifically highlighting chronic kidney disease (CKD) and acute kidney injury (AKI).
- The patent encompasses both composition of matter claims for specific chemical structures and method of use claims for therapeutic applications, providing broad intellectual property protection.
- This patent represents ongoing innovation in the SGLT2 inhibitor field, distinct from existing approved therapies, and positions Merck to develop new treatments for kidney diseases as patents for first-generation SGLT2 inhibitors expire.
- Commercial implications include market exclusivity for new drug candidates, potential barriers for competitors, licensing opportunities, and the strategic valuation of Merck's R&D assets.
Frequently Asked Questions
What specific chemical structure does U.S. Patent 11,975,017 cover?
The patent covers compounds of a specific bicyclic heterocycle, designated as compound (I), and their pharmaceutically acceptable salts. The exact structure and permissible variations are detailed in the patent's claims, particularly Claim 1.
What diseases are targeted by the methods described in Patent 11,975,017?
The patent claims methods of treating diseases mediated by SGLT2 inhibition, with specific mention of chronic kidney disease (CKD), acute kidney injury (AKI), diabetic kidney disease (DKD), and renal fibrosis.
Does this patent cover existing SGLT2 inhibitors like Jardiance or Farxiga?
No, U.S. Patent 11,975,017 covers novel bicyclic heterocycle compounds that are distinct from the chemical structures of established SGLT2 inhibitors such as empagliflozin (Jardiance) or dapagliflozin (Farxiga).
When does the market exclusivity provided by this patent begin and end?
Market exclusivity begins with the grant date of the patent, April 16, 2024, and generally extends for 20 years from the patent application's filing date, subject to potential patent term extensions.
What is the significance of this patent in the context of expiring SGLT2 inhibitor patents?
The patent is significant because it establishes new intellectual property protection for a novel class of SGLT2 inhibitors, allowing Merck to develop and potentially commercialize new therapies for kidney diseases even as patents for earlier SGLT2 inhibitors expire, thereby maintaining a competitive presence in the market.
Citations
[1] U.S. Patent No. 11,975,017 (U.S. April 16, 2024).
More… ↓
⤷ Start Trial
|
